Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Depreciation & Amortization (CF) (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Depreciation & Amortization (CF) data on record, last reported at $202000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 1.0% year-over-year to $202000.0; the TTM value through Dec 2025 reached $855000.0, up 22.14%, while the annual FY2025 figure was $855000.0, 22.14% up from the prior year.
  • Depreciation & Amortization (CF) reached $202000.0 in Q4 2025 per TARS's latest filing, down from $253000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $253000.0 in Q3 2025 and bottomed at $40000.0 in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $146100.0, with a median of $150000.0 recorded in 2024.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 635.29% in 2021, then plummeted 35.94% in 2022.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $40000.0 in 2021, then skyrocketed by 145.0% to $98000.0 in 2022, then soared by 148.98% to $244000.0 in 2023, then dropped by 18.03% to $200000.0 in 2024, then increased by 1.0% to $202000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $202000.0 in Q4 2025, $253000.0 in Q3 2025, and $200000.0 in Q2 2025.